Entries |
Document | Title | Date |
20100267641 | PROGNOSTIC TESTS FOR DEVELOPMENT OF DERMAL STRETCH MARKS AND IMPLICATIONS FOR THE PREVENTATIVE TREATMENT THEREOF - Various methods of assessing the regenerative potential of dermal tissue in a patient may be determined and methods to determine the potential development of stretch marks in a patient are provided. Through the analysis of a series of dermal tissue samples, a method of monitoring the aging process of the dermal tissue of a patient is possible. Damaged or stretched marked skin may also be used in the development of various diagnostic therapies relating to the inducement of the extracellular matrix components of the skin due to the loss of elastic fibers generally found in stretch marked skin. | 10-21-2010 |
20100273717 | Use of an Extract from the Vigna Aconitifolia Plant in a Cosmetic and/or Dermopharmaceutical Composition - An active composition for treating skin having a protein-containing extract from a | 10-28-2010 |
20100286055 | USE OF WNT3A FOR ACCELERATION OF WOUND HEALING - Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for accelerating wound healing. Also provided is a method of accelerating wound healing, the method comprising providing a therapeutically effective amount of WNT3 A, or a therapeutically effective fragment or derivative thereof, to a site where wound healing is to be accelerated. The medicaments and methods of the invention may be of particular use in accelerating the healing of skin wounds. | 11-11-2010 |
20100311666 | COSMETIC USE OF A PROTEIN BELONGING TO THE RIBONUCLEASE FAMILY - The present invention relates to the use, in cosmetics and in therapeutics, of at least one antimicrobial protein belonging to the ribonuclease family, ribonuclease 7, or of polypeptides derived from said protein, notably as a marker for evaluating the condition of the epidermis. It further relates to the use of at least one polypeptide according to the invention, of at least one nucleic acid sequence coding for a polypeptide according to the invention, or of at least one agent that modulates the expression or the activity, notably biological, of said polypeptide or of its interaction with an element of the extracellular matrix, for the preparation of compositions intended for the prevention and/or treatment of skin disorders. | 12-09-2010 |
20100317590 | REGULATION OF SKIN CHARACTERISTICS BY DICKKOPF1 (DKK1) - The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype. | 12-16-2010 |
20100317591 | USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES - This invention provides a method of treating a subject suffering from a dermatologic condition, including, inter alia, psoriasis, contact dermatitis, and seboreic dermatitis, the method includes the step of administering to a subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, in an amount effective to treat the subject suffering from a dermatologic condition. | 12-16-2010 |
20110009332 | Therapeutic Treatment Of Wounds - The present disclosure relates to compositions and methods for treating wounded skin and/or increasing the mechanical strength of wounded skin through the administration of an effective amount of a proteasome inhibitor to such wounded skin. | 01-13-2011 |
20110028403 | HSP70-Based Treatment for Autoimmune Diseases and Cancer - A non-natural HSP70 activating region that activates dendritic cells. Polypeptides that bind to the HSP70 activating region can be used to treat autoimmune diseases, such as vitiligo, by binding to HSP70 and preventing HSP70 form activating dendritic cells. The HSP70 binders can be constructed in the form of fusions proteins with a trimerizing structural element that may associate to form a trimeric complex. Pharmaceutical compositions and methods for treating vitiligo using the HSP70 binding proteins, fusion proteins and complexes. | 02-03-2011 |
20110053860 | COX-2 function and wound healing - The invention relates to compositions and methods for enhancing bone healing, bone formation and wound healing. More specifically, it relates to the use of cyclooxygenase 2 (COX-2) following bone fracture, orthopaedic procedure or wound infliction to enhance healing. | 03-03-2011 |
20110059896 | USE OF FURIN CONVERTASE INHIBITORS IN THE TREATMENT OF FIBROSIS AND SCARRING - The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions. | 03-10-2011 |
20110059897 | Methods for treating a skin wound - A therapeutic method for treating a skin wound involving administering to a patient in need thereof a composition containing pharmaceutically effective amounts of the following components: (1) a peptide consisting of the amino acid sequence represented by Ser-Ser-Ser-Arg (SEQ ID NO: 1) or pharmaceutically acceptable salts thereof and (2) a peptide consisting of the amino acid sequence represented by Phe-Gly-Leu-Met-NH | 03-10-2011 |
20110086805 | IN VITRO METHOD FOR DIAGNOSING SKIN CANCER - The present invention relates to an in vitro method for identifying an individual suffering from or having a predisposition to skin cancer, characterized in that it comprises the step of analysing a biological sample originating from said individual by a) detecting a polymorphism of the MATP/SLC45A2 gene (SEQ ID NO: 1), and/or analysing the expression of the MATP/SLC45A2 gene; to the use, for preparing a composition for the treatment and/or prevention of a skin cancer in an individual, of a compound which specifically increases the expression of the MATP/SLC45A2 gene in a skin cell; and to a method for the selection, in vitro, of a compound capable of being of use in the treatment of skin cancer. | 04-14-2011 |
20110092437 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 - The present application relate to cyclic depsipeptides, or derivatives thereof, having the formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7. | 04-21-2011 |
20110098229 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS - Provided herein are methods of improving one or more symptoms of a dermatological condition in a patient. The methods comprise topically administering a topical composition to the patient comprising a branched chain amino acid, and an enzyme activator. Also provided are kits comprising the topical composition and optionally a topical steroid. | 04-28-2011 |
20110118190 | Postsynaptically Targeted Chemodenervation Agents and Their Methods of Use - Improved chemodenervation agents are provided comprising polypeptide α-neurotoxins having high binding specificity and selectivity for the human muscular α1 nAChR instead of the human neuronal α7 nAChR, along with pharmaceutical compositions and methods of use. | 05-19-2011 |
20110124573 | Osmoprotective Complexes for Prevention of Intra-cellular Dehydration in Mammals - This invention relates to certain Aloesin derivatives with natural amino acids, peptides, and amino sugars (formula I). The compounds of the present invention possess osmoprotective properties, which are suitable for topical or oral application to treat dermatological disorders including challenged skin from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial dysfunction, age spots, acne, loss of cellular antioxidants, collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles including fine lines, oxidation, damage from radiation, damage from free radicals, damage from UV, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, liver spots, pigmented spots, dark circles under the eyes, skin pigmentation including darkened skin, blemishes, oily skin, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, topical inflammation, disturbed keratinization, skin changes associated with aging, scalp dryness, skin depigmentation, intracellular dehydration, and combinations thereof: | 05-26-2011 |
20110166076 | Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases - The present invention relates to superantigen-specificantigen-binding proteins comprising an immunoglobulin-derived variable domain that comprises a complete antigen binding site for an epitope on the superantigen in a single polypeptide chain. The antigen-binding proteins of the invention may be used in the treatment skin diseases. The antigen-binding proteins of the invention may be used in compositions for topical administration. | 07-07-2011 |
20110172160 | HEAT-STABLE, AQUEOUS LACTOFERRIN COMPOSITION AND ITS PREPARATION AND USE - The invention pertains to an aqueous composition containing lactoferrin, 35-70 wt % carbohydrate and/or polyol stabilizers, based on the total weight of the aqueous composition, said composition exhibiting a pH higher than 2, lower than 5. At these 5 conditions, the aqueous composition and lactoferrin contained therein may be subjected to a heat treatment without significantly affecting the physiological activity of the lactoferrin. The invention thus particularly pertains to the above aqueous composition, being heat-treated, thus containing heat-stabilized lactoferrin. | 07-14-2011 |
20110201559 | New Optically Pure Compounds for Improved Therapeutic Efficiency - The present invention relates to new optically pure compounds displaying an improved anticancer activity compared to previously known complex mixtures of stereoisomers thereof. Such compounds are of formula (I): wherein each X independently represents any amino acid; n is 0 or 1; m is an integer between 0 and 3; k is an integer of at least 3; Psi is a reduced bond of formula replacing the peptide amide bond between Lys and Pro; and wherein Lys residues in pseudopeptide units of said compound of formula (I) are either all in L configuration or all in D configuration. A method for preparing such compounds, and therapeutic uses thereof are also provided. The synthetic method involves the selective reduction of the peptide bond between Lys and Pro in a dipeptide intermediate with borane. The therapeutic uses are against cancer, inflammation and for wound healing. | 08-18-2011 |
20110237516 | PLANT-DERIVED ELASTIN BINDING PROTEIN LIGANDS AND METHODS OF USING THE SAME - The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents. | 09-29-2011 |
20110245181 | Compositions and Methods for Skin Treatment - Compositions for the treatment of the skin. The compositions reduce and/or reverse the visible appearance of skin damage. In the preferred embodiment, the composition includes Retinyl Palmitate Polypeptide; Ascorbylmethylsilanol Pectinate; Tocopheryl Polypeptide; Cholecalciferol Polypeptide; and Niacinamide Polypeptide. | 10-06-2011 |
20110263508 | Compositions and methods for including melanogenesis in a subject - Described herein are compositions comprising an alpha-MSH analogue and a transdermal delivery system and methods for inducing melanogenesis and/or preventing UV radiation-induced skin damage in a subject by topical administration of these compositions. | 10-27-2011 |
20110269691 | Compositions and Methods for Treating Pigmentary Conditions and Melanoma - A method of treating a hypopigmentary condition in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. The hypopigmentary condition can be a result of surgery, trauma or vitiligo. A method of treating a hyperpigmentary condition in a subject comprising administering to the subject an amount of inhibitor of SOX9 activity sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering to the subject an amount of prostaglandin D2 (PGD2) and retinoic acid (RA) sufficient to treat cancer. A method of sensitizing a melanoma cell to RA comprising administering to the subject an amount of SOX9 sufficient to decrease PRAME expression. A method of increasing p21 expression in a subject comprising administering to the subject an amount of SOX9 sufficient to increase p21 expression. Methods of screening for compounds that treat hypopigmentary conditions and/or melanoma are provided. | 11-03-2011 |
20110269692 | ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF - Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and/or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-dependent and estrogen-independent growth of cells, and treating or preventing cancer, such as breast cancer, brain cancer, head-and-neck cancer, thyroid cancer, lung cancer, colon cancer, ovarian cancer, prostate cancer, cervical cancer, and skin cancer. The treatment or prevention methods can include the use of tamoxifen therapy in combination with the peptide therapy. | 11-03-2011 |
20110288031 | IDENTIFICATION OF A NOVEL BHD GENE - The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating BHD skin lesions. | 11-24-2011 |
20110301090 | SKIN WOUND HEALING COMPOSITIONS AND METHODS OF USE THEREOF - A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90α or the middle domain plus the charged sequence of hsp90α. The composition is topically applied to skin wounds, covering the outer surface of the wound. The heat shock protein acts by promoting migration of both human epidermal keratinocyte and dermal fibroblasts to the wound in order to close, heal, and remodel the wound. | 12-08-2011 |
20110306560 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES - Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses. | 12-15-2011 |
20120010149 | PEPTIDE COMBINATION - The invention relates to a peptide combination characterized by peptides each having the same sequence length (SEQL), that can be produced from a mixture (A) comprising a number x of amino acids having a protected acid group or a number z of peptides having an acid group protected by means of a protecting group and an activated amino group, wherein the amino acids are present in the mixture (A) in particular adjustable molar ratios, and a mixture (B) comprising a number y of amino acids having an amino group protected by means of a protecting group, wherein the amino acid molar ratios of the mixture (B) are equal to the amino acid molar ratios of the mixture (A), and wherein the number x=y. | 01-12-2012 |
20120010150 | LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT - The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies. | 01-12-2012 |
20120065144 | Peptide for the Prophylactic or Therapeutic Treatment of Skin Tumors in Initial Stages - It comprises an inhibitor peptide of TGF-β1 for use in preventive or therapeutic treatment of skin tumors at early stages, in which the peptide is disitertide or a derivate thereof, and a pharmaceutical composition that comprises a therapeutically effective amount of the peptide. | 03-15-2012 |
20120088733 | NOVEL USE OF ANTIMICROBIAL PEPTIDES IN REGENERATION OF SKIN CELLS - Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. | 04-12-2012 |
20120129785 | COMPANION ANIMAL NUTRITION SYSTEM - The invention encompasses a nutrition system for a companion animal that includes a plurality of pet food packets, wherein an amount of pet food corresponding to a single meal for a companion animal may be selected and wherein the amount of pet food is formulated to alleviate or manage a disorder in a companion animal. In various embodiments, the pet food packets include the nutritional requirements for a companion animal (e.g., protein, fiber, fat) as well as one or more ingredients that alleviate or manage a disorder in a companion animal. | 05-24-2012 |
20120142605 | METHODS OF TREATING PSORIASIS - The invention includes methods for treating patients having psoriasis and methods for testing the efficacy of such treatments. The methods include treating the patients with a TNF inhibitor plus a topical preparation containing a glucocorticoid. | 06-07-2012 |
20120157387 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN - Provided are compounds which are prodrugs of D-gamma-glutamyl-D-tryptophan, methods of making the compounds and methods for using the compounds. | 06-21-2012 |
20120184493 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS - Described herein are topical formulations for use in the treatment or prevention of dermatological diseases, disorders, or conditions in a mammal. Topical formulations disclosed herein include a DP | 07-19-2012 |
20120214743 | ITCH SUPPRESSANT - The present invention provides an itch suppressant containing cholecystokinin 2 receptor agonist such as a peptide having an amino acid sequence homologous with a partial amino acid sequence of at least seven C-terminal amino acids of the peptide having the amino acid sequence represented by SEQ:ID No. 1 as an active ingredient as a rapid-acting itch suppressant effective in treating skin illnesses associated with strong itch such as atopic dermatitis having few side effects. | 08-23-2012 |
20120220536 | USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS - C-terminal endostatin polypeptides are disclosed herein. In some embodiments, these polypeptides include or consist of (1) at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; (2) at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions, (3) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; or (4) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions; wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung. | 08-30-2012 |
20120238505 | Medicaments - The present invention relates to the use of a peptide, or derivative thereof of general formula X1-X2-X3-ThT-X4-LyS-X5-ATg-X6 for promoting accelerated wound healing with reduced scarring. X1 is Ala or Gly; X2 is Tyr or Phe; X3, X4 and X5 are independently selected from the group comprising Met, He, Leu and Val; and X6 is selected from the group comprising Asp, Gln and Glu. | 09-20-2012 |
20120245097 | USE OF PEDF-DERIVED POLYPEPTIDES FOR PROMOTING STEM CELLS PROLIFERATION AND WOUND HEALING - Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing. | 09-27-2012 |
20120252735 | TREATMENT OF SKIN CONDITIONS BY DICKKOPF1 (DKK1) - The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype. | 10-04-2012 |
20130012449 | SOLVENT-FREE PROCESS FOR OBTAINING PHOSPHOLIPIDS AND NEUTRAL ENRICHED KRILL OILS - The invention discloses a new solvent-free process for obtaining phospholipids and neutral lipids enriched krill oils containing DHA and EPA poly-unsaturated fatty acids and astaxanthin. The process includes cooking fresh krill at high temperature-without agitation and or grinding; decanting the cooked krill for obtaining a partial de-fatted and de-watered solid and a liquid; squeezing the obtained solid to obtain a press liquid and a solid fraction; centrifuging the press liquid to obtain the phospholipids enriched krill oil; centrifuging of the decanter liquid obtained to obtain the neutral lipid enriched krill oil and stickwater. | 01-10-2013 |
20130023480 | Purified Bowman-Birk Protease Inhibitor Proteins Isolated from a Soy Processing Sttream - Purified Bowman-Birk protease inhibitor (BBI) proteins recovered from a soy processing stream are disclosed, as well as a process for recovering and isolating purified BBI proteins from a soy processing stream. | 01-24-2013 |
20130059790 | PROCESS FOR THE PREPARATION OF A BIOMASS COMPRISING PLANTARICIN AND USES THEREOF IN MEDICAL FIELD - The present invention concerns a process for preparation of a biomass comprising one or a more plantaricins A, N or K in association with the lactic acid bacteria used for the preparation and uses thereof in order to stimulate the barrier function of intestinal cells or human epidermal keratinocytes. | 03-07-2013 |
20130065835 | PROGNOSTIC TESTS FOR DEVELOPMENT OF DERMAL STRETCH MARKS AND IMPLICATIONS FOR THE PREVENTATIVE TREATMENT THEREOF - Various methods of assessing the regenerative potential of dermal tissue in a patient may be determined and methods to determine the potential development of stretch marks in a patient are provided. Through the analysis of a series of dermal tissue samples, a method of monitoring the aging process of the dermal tissue of a patient is possible. Damaged or stretched marked skin may also be used in the development of various diagnostic therapies relating to the inducement of the extracellular matrix components of the skin due to the loss of elastic fibers generally found in stretch marked skin. | 03-14-2013 |
20130123190 | Methods for Treating Combined Radiation and Thermal Injury - The present invention provides methods for treating a subject that has suffered combined exposure to total body ionizing irradiation and burns. | 05-16-2013 |
20130184220 | TREATMENT OF ABNORMAL OR EXCESSIVE SCARS - Methods and compositions comprising combinations and uses of a first anti-connexin agent and a second anti-connexin agent, for example, one or more anti-connexin polynucleotides and one or more anti-connexin peptides or peptidomimetics, are provided for the treatmen or prevention of abnormal or excessive scarring. | 07-18-2013 |
20130225501 | SKIN COLLAGEN PRODUCTION-PROMOTING AGENT - Skin quality is improved by orally administering a cystatin and/or a degraded product of cystatin in an amount of 10 μg/day or more per adult, or applying a composition that includes a cystatin and/or a degraded product of cystatin in an amount of 0.001 to 2 wt % based on a total amount of the composition. | 08-29-2013 |
20130267471 | Formulations and methods of use for alpha connexin C-terminal (ACT) peptides - This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided. | 10-10-2013 |
20130274197 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS - The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone. | 10-17-2013 |
20130316956 | NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF - The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like. | 11-28-2013 |
20130331331 | HEXAPEPTIDE WITH IMPROVED ACTIVITY IN THE REPAIR OF CELLULAR DNA OF DERMAL CELLS - The present invention relates to a compound having a structure selected from: Ac-Nle-Glu-His-D-Phe-Arg-Trp-NH | 12-12-2013 |
20140005116 | KELOID TREATMENT | 01-02-2014 |
20140031296 | NEW SYNTHETIC PEPTIDES AND THEIR USE - The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumours. | 01-30-2014 |
20140194365 | USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS - C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung. | 07-10-2014 |
20140200185 | CYCLOSPORIN DERIVATIVES FOR TREATING OCULAR AND DERMAL DISEASES AND CONDITIONS - The present invention provides a method for the treatment of ocular or dermal diseases and/or conditions, e.g. an aqueous deficient dry eye state, uveitis or phacoanaphylactic endophthalmitis in an eye, or balanitis, psoriasis, or atopic dermatitis of the skin, said method comprising administering, topically to the eye or the skin, a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: | 07-17-2014 |
20140303089 | Plant HSP70 for Use in the Treatment of Food Allergy - Object of the invention is to provide a treatment for food allergy, in particular for peanut or milk allergy. This object was met by providing a plant Hsp70 or a hydrolysate thereof for use in the prophylactic or therapeutic treatment of a food allergy. | 10-09-2014 |
20140371154 | NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF - The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like. | 12-18-2014 |
20140371155 | NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF - The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like. | 12-18-2014 |
20150018284 | FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES - This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided. | 01-15-2015 |
20150025015 | KERATIN COMPOSITIONS COMPRISING HALOFUGINONE - Described herein are compositions of keratin-based biomaterials together with halofuginone and methods of using thereof | 01-22-2015 |
20150038427 | COLLAGEN-BINDING SYNTHETIC PEPTIDOGLYCANS FOR WOUND HEALING - Methods and compositions for promoting wound healing in a patient by administering a collagen-binding synthetic peptidoglycan to the patient are described. Additionally, methods and compositions are described for decreasing scar formation in a patient by administering a collagen-binding synthetic peptidoglycan to the patient. | 02-05-2015 |
20150045307 | IDENTIFICATION OF A NOVEL BHD GENE - The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating BHD skin lesions. | 02-12-2015 |
20150065431 | REDUCING CUTANEOUS SCAR FORMATION AND TREATING SKIN CONDITIONS - The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the Na | 03-05-2015 |
20150065432 | VISFATIN THERAPEUTIC AGENTS FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS - The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions. | 03-05-2015 |
20150072936 | METHODS FOR PROMOTING WOUND HEALING AND/OR REDUCING SCAR FORMATION - The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein. | 03-12-2015 |
20150290252 | ADMINISTRATION OF CELLS AND CELLULAR EXTRACTS FOR REJUVENATION - The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products. | 10-15-2015 |
20150299266 | BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING - There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure wherein the material comprises a pair of self assembling complementary polypeptides. | 10-22-2015 |
20150306175 | HSP For Use in Treatment for Imiquimod Related Side Effects - The invention relates to a healthcare product comprising (i) a component selected from the group of heat shock proteins from alfalfa and heat shock protein hydrolysates from alfalfa, the product further comprising imiquimod or a pharmaceutically acceptable salt or derivative thereof. Further, the invention relates to a healthcare product for use in the prophylactic or therapeutic treatment of a skin disorder. Further, the invention relates to HSP for use for use in preventing the occurrence of a negative-side effect of a treatment with imiquimod, or alleviating such side effect. | 10-29-2015 |
20150352196 | Methods and Pharmaceutical Compositions for Prevention of Aging-Related Lesions - The present invention relates to methods and compositions for prevention of aging-related lesions. More particularly, the present invention relates to a calpain inhibitor compound for use in a method for preventing aging-related lesions in a subject in need thereof. | 12-10-2015 |
20150353612 | NUCLEIC ACIDS ENCODING PEPTIDES FOR TREATING WOUNDS, ANTI-ANGIOGENIC COMPOUNDS AND USES THEREOF - The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present disclosure include antisense oligonucleotides that hybridize or are complementary to the polynucleotides of SEQ ID NOs: 5-16, and the like. | 12-10-2015 |
20160038462 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS - The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent. | 02-11-2016 |
20160038563 | MOLECULAR TARGETS FOR HEALING OR TREATING WOUNDS - The invention relates to at least one molecular target for healing or treating wounds and, in particular chronic, human wounds. The molecular target is nWASP or a protein at least 75% homologous therewith and which retains the same activity as nWASP protein, such as WASP. Further, the invention concerns a novel therapeutic for treating said wounds and a novel gene therapy approach, involving said molecular target, for treating said wounds. | 02-11-2016 |
20160058834 | FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES - This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided. | 03-03-2016 |
20160095898 | YERSINIA OUTER PROTEIN M (YOPM) IN THE TREATMENT OF PSORIASIS - The present invention relates to the use of | 04-07-2016 |
20160095931 | COMPOSITIONS CONTAINING HC-HA COMPLEX AND METHODS OF USE THEREOF - Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof. | 04-07-2016 |
20160106799 | Carbohydrate Compounds for Nutritional and Therapeutic Use - Embodiments of the present invention provide compositions and methods for the modulation of sialic acid levels. In some embodiments, compositions disclosed herein comprise nutraceuticals as functional agents. | 04-21-2016 |
20160129077 | Use of recombinant ganoderma immunoregulatory protein (rLZ-8) in preparation of drug for treating melanoma - A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma. | 05-12-2016 |
20160193293 | OINTMENT CONTAINING A HYDROLYZED FIBROIN AND MANUFACTURING METHOD OF SAME | 07-07-2016 |
20170232064 | FORMULATIONS FOR HISTATIN THERAPEUTICS | 08-17-2017 |